Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.58 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | ACACB | O00763 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5380768 | 0.85 | LTA4H (0.57) | LTA4HNPY5RALOX5NPC1RAB9A | |
| SCHEMBL6266373 | 0.85 | LTA4H (0.59) | LTA4HALOX5NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7444074 | 0.85 | LTA4H (0.62) | LTA4HALOX5NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10603321 | 0.85 | LTA4H (0.62) | LTA4HALOX5NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7070156 | 0.84 | LTA4H (0.56) | LTA4HNPY5RALOX5NPC1RAB9A | |
| SCHEMBL31579489 | 0.83 | LTA4H (0.60) | LTA4HALOX5NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4600612 | 0.82 | L3MBTL1 (0.58) | NPY5RALOX5RAB9ASMN1; SMN2LMNA | |
| SCHEMBL2840120 | 0.82 | LTA4H (0.59) | LTA4HALOX5NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3882630 | 0.81 | LTA4H (0.50) | LTA4HALOX5NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3882627 | 0.81 | LTA4H (0.50) | LTA4HALOX5NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7102008-B2 | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-05 | — | — | US | disclosed |
| US-20040063698-A1 | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
| WO-2004012663-A2 | HYDANTOIN DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-ALPHA CONVERTING ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063698-A1 | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme | MMP9, ADAM17, MMP3 | LTA4H 492/4885NPY5R 1562/4885ALOX5 2741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.